$2.58-0.02 (-0.77%)
Cerus Corporation operates as a biomedical products company.
Cerus Corporation in the Healthcare sector is trading at $2.58. Wall Street consensus targets $4.67 (3 analysts), implying a +80.9% move over the next 12 months. The stock is currently 18% below its 52-week high of $3.15, remaining 31.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling...
Here is how BrightSpring Health Services, Inc. (BTSG) and Cerus (CERS) have performed compared to their sector so far this year.
Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, […]
Over the last 7 days, the United States market has dropped by 1.0%, but it remains up 23% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic landscape, identifying stocks that combine value and growth potential is key, especially when considering smaller or younger companies often referred to as penny stocks. Though the term may seem outdated, these investments can still offer significant opportunities for those looking to discover under-the-radar...
Epistrophy Capital Research Chief Market Strategist and The Drill Down Podcast host Cory Johnson joins Market Catalysts to discuss the Cerebras IPO and key factors to watch in Nvidia’s (NVDA) upcoming earnings report.
Moby summary of Cerus Corporation's Q1 2026 earnings call